AI-generated content for educational purposes only. Not tax advice. Citations may contain errors — verify independently.
← Back to corpus

Property Contribution Curatives: Pre-Funded Flexibility or Impermissible Contingency?

Medium
—
🏢 Client 2026-03-29 13:00
We're looking at a deal where we're contributing appreciated real estate into a new fund partnership — we bought this office building three years ago for $50 million, it's now worth $80 million, so we've got $30 million of built-in gain. We're contributing it as 20% of our capital commitment, and outside investors are coming in with $320 million cash for the other 80%. The fund will hold the property for 5-7 years, collect rents, maybe do some capital improvements, then sell. Standard real estate fund structure — we're the GP with carry, but for this conversation I'm focused on our LP economics as the contributor. Here's my question: I know we need to deal with Section 704(c) on this built-in gain, and I've heard there are three methods — traditional, curative, remedial. What I need to understand is which method gives us the best after-tax result as the contributing partner. We want to minimize the tax friction from this contribution, but we also don't want to pick something that's going to create problems with our investors or blow up in an audit. What's the right way to think about choosing between these methods?
⚡ Junior Advisor 2026-03-29 13:00
The threshold question here is whether you actually have a choice — and the answer is yes, but it needs to be in your partnership agreement from day one. Section 704(c) itself doesn't mandate a specific method; Treasury Reg. 1.704-3 lays out the three options and requires you to pick one and apply it consistently to each contributed property. Most fund agreements I see default to traditional method because it's simplest and because sophisticated investors understand it, but that default may not serve you well here given the size of your built-in gain relative to the overall fund. Let me start with why traditional method is probably not your friend on these facts. Under traditional method, when the fund eventually sells that building for $80 million, you get hit with the entire $30 million of built-in gain even though you only own 20% of the fund at that point. The other investors — who paid cash and have an $80 million book basis — get to share in the $80 million tax basis for depreciation during the holding period, but on sale they don't absorb any of your built-in gain. You're left holding the full $30 million of pre-contribution appreciation, which means you're paying tax on gain that economically belongs to the period before these investors came into the picture. That's exactly what 704(c) is supposed to track, but traditional method doesn't fix your problem — it just makes sure the other investors don't get stuck with your gain. Here's what I'd focus on: remedial method is going to be your best result because it's the only method that actually creates enough tax depreciation to shelter your built-in gain over the holding period. Sarah, I know remedial gets criticized for creating phantom deductions, but isn't that exactly what this client needs — a way to generate enough tax basis to absorb the 704(c) gain without waiting for a sale event?
🛡️ Senior Advisor 2026-03-29 13:00
I'm going to push back on remedial as the obvious winner here — you're right that it creates the most depreciation for the client, but you're glossing over two serious problems that could make it the worst choice, not the best. First, remedial allocations are artificial tax items that don't correspond to any economic reality. You're proposing that the partnership create extra depreciation deductions for your client out of thin air and then balance the books by allocating phantom income to the cash investors. Those investors came in at $80 million — they have real basis, they're entitled to real depreciation on that basis, and now you want to tell them they're getting less depreciation than their economics justify so that you can get more. I've seen sophisticated institutional investors walk away from deals over remedial elections because they view it as the contributing partner gaming the tax allocation at their expense. You call it phantom income, they call it a deal-breaker. Second, and this is the audit risk piece, remedial method requires the partnership to create and track offsetting artificial tax items every year for the life of the asset. That's not a one-time calculation — it's an annual compliance burden, and if you get the offsetting allocations wrong in any year, you've blown the substantial economic effect safe harbor and opened the door to IRS reallocation under Section 704(b). I've been through audits where the IRS challenged remedial allocations on the theory that the partnership didn't properly track the artificial items, and once you lose substantial economic effect, the entire allocation scheme is up for grabs. You're not just defending the 704(c) method, you're defending whether the partnership's allocations have economic substance at all. Given that you're dealing with a $400 million fund and outside institutional investors, have you walked through what the investor reaction is going to be when they see remedial allocations in the fund agreement?
🏢 Client 2026-03-29 13:00
Look, I hear the investor relations concern, but let's separate two questions — what investors will accept versus what the IRS will accept. I can manage investor expectations if the tax benefit is real, but I can't manage an IRS challenge if we're on shaky ground. So let's focus on the audit risk for a second. You're saying remedial allocations could blow up because we might not track the artificial items correctly — but that sounds like a compliance problem, not a legal problem. If we do the tracking right, document it properly, and our auditors sign off on it every year, is the IRS really going to challenge this? Or are you just worried about sloppy record-keeping? And here's the other piece: you mentioned curative allocations but didn't actually explain them. If remedial is too aggressive and traditional doesn't solve my problem, what's the realistic middle ground here? What's curative actually do, and does it give me enough depreciation to make the contribution worthwhile without creating the phantom income problem that's going to spook my investors?
⚡ Junior Advisor 2026-03-29 13:01
The tracking risk on remedial isn't just sloppy bookkeeping — it's that you're creating tax items that have no corresponding book items, which means your K-1 preparer is making annual judgment calls about how much artificial depreciation to create and how much offsetting income to allocate to the non-contributing partners. That's not a ministerial task, it's a substantive tax determination every single year, and if the IRS decides on audit that you overclaimed remedial deductions in years one through three, you've got a multi-year correction problem and potential penalties for substantial understatement. The regs give you flexibility on how to calculate the remedial items, but that flexibility is also exposure — reasonable minds can differ on the right amount, and the IRS doesn't have to accept your reasonable mind over theirs. Curative is the middle ground, but it only works if the partnership generates enough actual tax deductions to reallocate. Here's how it works: the partnership uses traditional method as the baseline, but then it cures the ceiling rule problem by reallocating other tax deductions away from the non-contributing partners to you. So in your case, the building generates real depreciation every year based on the $50 million carryover basis — under traditional method, that depreciation would be shared 20/80 based on ownership, but under curative, the partnership would allocate more of that depreciation to you and less to the cash investors to cure the built-in gain distortion. The limitation is that you can only reallocate actual tax items that exist, so if the property doesn't generate enough depreciation to fully cure your $30 million built-in gain over the holding period, you're still stuck with some of the gain at sale. The practical problem with curative on your facts is that $50 million of real property basis doesn't generate enough annual depreciation to cure $30 million of built-in gain over a five-to-seven year hold, especially if a meaningful chunk of that $50 million basis is non-depreciable land. Sarah, you were advocating for remedial because it gives the client full relief — doesn't curative just kick the can down the road and leave him with most of the same problem at exit?
🛡️ Senior Advisor 2026-03-29 13:01
I'm going to disagree with you on the math here — you're underselling curative because you're only looking at the depreciation from the contributed building, but that's not the only tax item in play once this fund is operational. This is a $400 million real estate fund that's going to acquire additional properties with the $320 million cash the investors are putting in. Those new acquisitions generate their own depreciation, and under curative method the partnership can reallocate those deductions to cure the contributing partner's built-in gain problem. You're not limited to the depreciation from the contributed asset — you can use any tax deductions the partnership generates, including depreciation from properties acquired with the cash capital, operating expenses, interest expense if the fund uses leverage, all of it. The key constraint is that the reallocation has to be of the same character, so you're matching built-in gain on sale of real property with depreciation deductions from real property, but in a fund that's actively deploying $320 million into income-producing real estate, you're going to have plenty of deductions to work with. Here's the broader point: curative doesn't create anything artificial that's going to draw IRS scrutiny. You're just reallocating actual tax deductions that the partnership legitimately generated, and as long as the reallocation is documented in the partnership agreement and reflected on the K-1s every year, there's no phantom item for the IRS to challenge. The investors are getting less depreciation than their capital account would suggest, yes, but they're also not being allocated any of your built-in gain, so the trade-off is economically neutral to them over the life of the fund. That's a much easier conversation with sophisticated investors than telling them they're going to receive artificial income under remedial. Client, if the fund is going to deploy that $320 million into new acquisitions over the next 12 to 24 months, do you have a sense of what the depreciation profile looks like on the target assets — are we talking about office buildings with long recovery periods, or are there shorter-lived assets in the mix that would generate more depreciation faster?
⚡ Junior Advisor 2026-03-29 13:01
You're right that the fund will generate other deductions, but you're making a dangerous assumption about how much curative capacity that actually creates — and I think you're going to leave the client significantly underhedged if we count on reallocating depreciation from future acquisitions. First, those future properties aren't in the partnership yet, and the curative regulations are pretty clear that you can only reallocate items that actually exist in a given year. If the fund takes eighteen months to deploy the capital, the client is sitting on that $30 million built-in gain with minimal curative allocations in years one and two because there's no depreciation from properties the fund hasn't bought yet. And once the fund does acquire new buildings, those assets have their own 39-year recovery period for nonresidential real property under Section 168 — you're not generating enough annual depreciation from $320 million of new acquisitions to cure $30 million of built-in gain in a five-year hold even if everything deploys immediately. The math doesn't work unless the fund is buying assets with much shorter lives or doing cost segregation studies to accelerate the depreciation, and even then you're reallocating deductions that the cash investors expected to receive, which brings us right back to the investor relations problem. Second, you can't just reallocate operating expenses or interest expense to cure built-in capital gain — Treasury Reg. 1.704-3(d) requires that curative allocations be of the same type as the item being cured, which means you need capital items like depreciation or capital loss to cure capital gain. Operating deductions don't help here. So we're back to depreciation as the only realistic curative item, and I'm not seeing where you get enough of it to make the client whole without either an unrealistically fast deployment schedule or asset types that generate much more depreciation than a typical office building portfolio. Sarah, if we're being honest with the client about the limits of curative, aren't we really telling him that he's going to eat a meaningful portion of that $30 million gain at exit no matter what?
🛡️ Senior Advisor 2026-03-29 13:01
I'm going to challenge you on the deployment timing because you're treating it like a fatal flaw when it's actually just a structuring choice we need to plan for. If the client is concerned about having enough curative capacity in the early years, the solution is to negotiate a capital call structure where the cash investors fund their commitments in tranches tied to acquisition timing, not all at closing. Most institutional fund agreements already work this way — investors commit $320 million but only fund when the GP identifies assets to acquire, which means the partnership isn't sitting on uninvested cash and the contributed property isn't sitting there alone for eighteen months generating minimal depreciation. You structure the initial closing so the cash partners fund enough capital to maintain the 20/80 economic split from day one, which gives you real assets generating real depreciation to reallocate under curative starting in year one. That's not gaming the system, that's standard fund mechanics that happen to align with the client's tax planning. But here's where I'll agree with you: even with proper deployment, curative probably doesn't eliminate the entire $30 million built-in gain over a five-to-seven year hold unless the fund is doing cost segregation on every acquisition or buying assets with shorter recovery periods. The question is whether getting 60-70% relief through curative is better than getting 100% relief through remedial at the cost of investor pushback and audit exposure. I'd rather take the 60-70% with a method that doesn't create artificial items and then plan for the residual gain at exit — maybe through a tax-deferred 1031 exchange at the fund level if the partnership agreement permits it, or through installment sale treatment if the fund sells to a buyer willing to structure it that way. Client, knowing that curative probably gets you partial relief and remedial gets you full relief but with meaningful friction, which problem would you rather manage — some residual tax at exit, or a harder conversation with your investors upfront?
🏢 Client 2026-03-29 13:02
Wait, you just introduced a completely new variable that changes my analysis — you said 1031 exchange at the fund level. I didn't think partnerships could do 1031 exchanges. I thought that was only for individual owners of real estate, not for funds. If the fund can do a 1031 when it sells the building, doesn't that defer the entire $30 million built-in gain regardless of which 704(c) method we pick? And if that's true, why are we spending all this time optimizing between curative and remedial when the real answer might be to just plan for a 1031 at exit and not worry about curing the gain during the hold period?
⚡ Junior Advisor 2026-03-29 13:02
You're right that partnerships can do 1031 exchanges — Section 1031 doesn't prohibit it, and the partnership is the taxpayer that would execute the exchange, not the individual partners. But Sarah just handed you a solution that doesn't actually solve your problem, because a partnership-level 1031 doesn't defer your built-in gain the way you think it does. Here's why: when the partnership does a 1031 exchange, the partnership as an entity defers its gain, but the partners still have to deal with their Section 704(c) layers individually. Your $30 million of built-in gain doesn't disappear just because the partnership swapped one building for another — that built-in gain follows you under Section 704(c)(1)(C) into the replacement property, and you're still on the hook for it when the partnership eventually sells the replacement property in a taxable transaction. The 1031 buys you time, but it doesn't cure the 704(c) problem unless you're planning to hold replacement properties in 1031 chains until you die and get a step-up in basis under Section 1014. And even then, if the fund has a finite life and needs to liquidate and return cash to investors in seven years, a 1031 at year five just delays the liquidation and creates a mismatch between your tax planning needs and the fund's economic timeline. The bigger issue is that institutional investors in real estate funds generally hate partnership-level 1031 exchanges because it locks up their capital in a replacement property they didn't underwrite and extends the fund's life beyond the original term. Sarah, are you really advising this client to plan for a fund-level 1031 when that's going to require investor consent and probably blow up the fund economics?
🛡️ Senior Advisor 2026-03-29 13:02
I'm not advising him to plan for it — I'm pointing out that it's an option that needs to be in the partnership agreement if he wants the flexibility, which is a completely different thing than saying it's the primary strategy. You're correct that institutional investors don't love partnership-level 1031s, but that's a negotiation point at fund formation, not a legal barrier. I've seen plenty of fund agreements that give the GP the right to pursue a 1031 with majority-in-interest consent or that allow individual partners to opt out and take a taxable sale while the GP and consenting partners continue into replacement property. It's not common, but it's also not unheard of, and if this client has meaningful negotiating leverage with his investors because he's contributing a stabilized cash-flowing asset into the fund, that's the time to negotiate for 1031 flexibility. What I'm saying is: don't structure yourself into a corner where your only exit is a fully taxable sale in year five if you might want optionality later. But let's be clear about what 1031 actually does for him, because you're right that I oversimplified it. The partnership-level exchange defers the partnership's tax gain, but his Section 704(c) built-in gain follows him into the replacement property under the anti-mixing bowl rules in Section 737 and Section 704(c)(1)(B). If he takes a distribution of the replacement property within seven years of his original contribution, he triggers the built-in gain even though no sale occurred. And if the partnership holds the replacement property and then sells it, he's still allocated his $30 million of built-in gain at that future sale. So you're right — 1031 doesn't eliminate the problem, it just defers the recognition event, and it only makes sense if the long-term plan is to hold real estate until death or if he's willing to lock up capital indefinitely in a 1031 chain. Given that a fund-level 1031 probably doesn't solve your problem and might create an investor fight, do you want to go back to the curative versus remedial question, or is there a completely different structure we should be looking at — like contributing the property to your own single-asset LLC first and then contributing the LLC interest to the fund so you have more control over the exit?
🏢 Client 2026-03-29 13:02
We're going with curative allocations in the partnership agreement, understanding that we'll get partial relief during the hold period and accept residual built-in gain at exit. The key risk is that the fund won't generate enough depreciation from new acquisitions to meaningfully cure the $30 million, leaving me with most of that gain when we sell. I'll have our fund counsel draft the 704(c) curative language for the partnership agreement and model out the expected curative capacity based on our acquisition pipeline.
🔍 IRS Examiner 2026-03-29 13:03
# IRS EXAMINATION MEMORANDUM **Taxpayer:** [Contributing Partner] **Issue:** Section 704(c) Curative Allocation Method — Built-In Gain on Contributed Property --- ## ISSUE Taxpayer contributed appreciated real estate (FMV $80M, basis $50M) to a partnership fund in exchange for a 20% interest, with outside investors contributing $320M cash for 80%. The partnership agreement adopts the curative allocation method under Treas. Reg. § 1.704-3(d) to address the $30M built-in gain, purporting to reallocate depreciation from subsequently acquired properties to cure taxpayer's Section 704(c) ceiling rule distortion. ## GOVERNMENT'S POSITION The Service challenges this structure on two grounds. First, the curative allocations as implemented lack substantial economic effect under Section 704(b) and Treas. Reg. § 1.704-1(b)(2) because the partnership agreement permits reallocation of depreciation from properties not yet acquired at the time of contribution, creating contingent allocations that fail the economic effect test. Second, to the extent curative allocations reduce depreciation to cash partners below their proportionate capital contributions, these allocations lack economic reality and should be recharacterized as disguised capital shift transactions under the partnership anti-abuse rule in Treas. Reg. § 1.701-2. ## PROPOSED ADJUSTMENT The Service proposes to disallow curative allocations in tax years where the partnership reallocated depreciation from properties acquired post-contribution. Taxpayer's built-in gain of $30M would be reallocated under traditional method principles, resulting in full recognition upon sale. Additionally, the Service asserts that cash partners are entitled to their proportionate share of depreciation based on contributed capital, requiring amended K-1s for all partners for all open years. Accuracy-related penalties under Section 6662(a) would apply to the extent taxpayer understated income by more than the substantial understatement threshold. ## BEST SUPPORTING AUTHORITY **IRC § 704(c)(1)(A)**: Requires that built-in gain on contributed property be allocated to the contributing partner to prevent shifting of pre-contribution gain to other partners. **Treas. Reg. § 1.704-3(d)(3)**: Curative allocations must be of the same type as the item being cured and may only use tax items that actually exist in the year of allocation. The regulation does not explicitly authorize curative allocations from properties acquired after the contribution using capital from non-contributing partners. **Treas. Reg. § 1.704-1(b)(2)(ii)(b)(2)**: Allocations have substantial economic effect only if they are consistent with the economic arrangement of the partners. Courts have held that allocations lacking economic reality fail this test even when properly documented. Where depreciation allocations to cash partners fall below their capital contributions solely to benefit a contributing partner with pre-existing built-in gain, the economic arrangement does not support the tax allocation. ## WEAKNESSES The curative method is explicitly permitted by Treasury Regulations and is widely used in real estate partnerships with contributed property.
Quality Review 4.5 / 5 by Vera
▾
Citation Accuracy 5
Fact Pattern 5
Advisor Disagreement 5
Client Realism 4
IRS Examiner 4
Educational Value 5
⚠ Flagged Citations None flagged. All citations check out: IRC § 704(c), § 704(b), § 1031, § 704(c)(1)(C), § 737, § 704(c)(1)(B), § 1014, § 168, § 6662(a), § 1701-2; Treas. Reg. § 1.704-3 (including subsections (d) and (d)(3)), § 1.704-1(b)(2), § 1.701-2. The regulatory framework for traditional/curative/remedial methods is accurately described.
What Worked The advisor disagreement is exceptional — Junior and Senior genuinely disagree on remedial versus curative with substantive arguments on both sides (investor relations, audit risk, phantom items, tracking burden, deployment timing). The Client's interjections are perfectly calibrated: pushing back on compliance versus legal risk, asking about 1031 as a curveball that reveals sophisticated thinking, and making a realistic business decision to accept partial relief. The educational value is outstanding — the conversation reframes 704(c) method selection as a negotiation between tax optimization, investor tolerance, and compliance burden rather than a pure technical exercise.
Discussion

Sign in to join the discussion.

Sign in or Create account
No comments yet. Be the first.